Loading organizations...
§ Private Profile · Falmer, East Sussex, United Kingdom
Clinical-stage biopharmaceutical company developing novel muco-regulatory therapies for respiratory diseases like CF, COPD, asthma.
Enterprise Therapeutics is a clinical-stage biopharmaceutical company based in Brighton, England, developing novel muco-regulatory therapies for respiratory diseases. The organization treats conditions like cystic fibrosis, chronic obstructive pulmonary disease, and severe asthma by targeting ion channels such as TMEM16A and ENaC to improve mucus hydration. To advance its drug discovery pipeline into clinical development, the company raised £29 million in an oversubscribed Series B funding round during April 2018. This financing was co-led by prominent healthcare investors Versant Ventures and Novartis Venture Fund, with additional participation from Forbion and IP Group. The enterprise operates under Chief Executive Officer Dr. John Ford and features industry veterans like Amit Munshi on its board of directors. While Epidarex Capital served as the initial founding investor, the exact founding year and the original individual founders remain publicly undisclosed.
Enterprise Therapeutics has raised $78.7M across 4 funding rounds.
Enterprise Therapeutics has raised $78.7M in total across 4 funding rounds.
Enterprise Therapeutics has raised $78.7M across 4 funding rounds. Most recently, it raised $33.0M Series B in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 30, 2024 | $33M Series B | ROB Woodman | Epidarex Capital, Forbion, Novartis, Versant Ventures | Announced |
| Apr 12, 2018 | $37M Series B | David Morris, MD, Alexander Mayweg | Elizabeth Roper, Geert JAN Mulder | Announced |
| Nov 10, 2016 | $5M Venture Round | Elizabeth Roper, ROB Woodman | — | Announced |
| May 19, 2015 | $3.7M Series A Plus | Imperial Innovations | Epidarex Capital | Announced |
Enterprise Therapeutics has raised $78.7M in total across 4 funding rounds.
Enterprise Therapeutics's investors include Rob Woodman, Epidarex Capital, Forbion, Novartis, Versant Ventures, David Morris, MD, Alexander Mayweg, Elizabeth Roper, Geert Jan Mulder, Imperial Innovations.